Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)

E. J. Shpall, R. E. Champlin, A. C. Eaves, A. P. Gee, N. Collins, C. F. LeMaistre, R. O'Reilly, S. D. Rowley, K. Sullivan, W. P. Vaughan, Phyllis Irene Warkentin

Research output: Contribution to journalShort survey

Abstract

We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolve as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near future.

Original languageEnglish (US)
Pages (from-to)287-289
Number of pages3
JournalJournal of hematotherapy
Volume6
Issue number4
DOIs
StatePublished - Jan 1 1997

Fingerprint

Accreditation
Cell- and Tissue-Based Therapy

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068). / Shpall, E. J.; Champlin, R. E.; Eaves, A. C.; Gee, A. P.; Collins, N.; LeMaistre, C. F.; O'Reilly, R.; Rowley, S. D.; Sullivan, K.; Vaughan, W. P.; Warkentin, Phyllis Irene.

In: Journal of hematotherapy, Vol. 6, No. 4, 01.01.1997, p. 287-289.

Research output: Contribution to journalShort survey

Shpall, EJ, Champlin, RE, Eaves, AC, Gee, AP, Collins, N, LeMaistre, CF, O'Reilly, R, Rowley, SD, Sullivan, K, Vaughan, WP & Warkentin, PI 1997, 'Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)', Journal of hematotherapy, vol. 6, no. 4, pp. 287-289. https://doi.org/10.1089/scd.1.1997.6.287
Shpall, E. J. ; Champlin, R. E. ; Eaves, A. C. ; Gee, A. P. ; Collins, N. ; LeMaistre, C. F. ; O'Reilly, R. ; Rowley, S. D. ; Sullivan, K. ; Vaughan, W. P. ; Warkentin, Phyllis Irene. / Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068). In: Journal of hematotherapy. 1997 ; Vol. 6, No. 4. pp. 287-289.
@article{5396589a2361437bb7dd40d4f15068ac,
title = "Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)",
abstract = "We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolve as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near future.",
author = "Shpall, {E. J.} and Champlin, {R. E.} and Eaves, {A. C.} and Gee, {A. P.} and N. Collins and LeMaistre, {C. F.} and R. O'Reilly and Rowley, {S. D.} and K. Sullivan and Vaughan, {W. P.} and Warkentin, {Phyllis Irene}",
year = "1997",
month = "1",
day = "1",
doi = "10.1089/scd.1.1997.6.287",
language = "English (US)",
volume = "6",
pages = "287--289",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)

AU - Shpall, E. J.

AU - Champlin, R. E.

AU - Eaves, A. C.

AU - Gee, A. P.

AU - Collins, N.

AU - LeMaistre, C. F.

AU - O'Reilly, R.

AU - Rowley, S. D.

AU - Sullivan, K.

AU - Vaughan, W. P.

AU - Warkentin, Phyllis Irene

PY - 1997/1/1

Y1 - 1997/1/1

N2 - We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolve as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near future.

AB - We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolve as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0030800526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030800526&partnerID=8YFLogxK

U2 - 10.1089/scd.1.1997.6.287

DO - 10.1089/scd.1.1997.6.287

M3 - Short survey

VL - 6

SP - 287

EP - 289

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 4

ER -